CANOPY-A: A phase III, placebo-controlled study of canakinumab as adjuvant therapy in patients (pts) with surgically resected NSCLC

被引：0

作者：

Cho, B. C. ^{[1
]}

Chang, G-C. ^{[2
]}

Kim, Y-C. ^{[3
]}

Geater, S. ^{[4
]}

Saeteng, S. ^{[5
]}

Yang, C-T. ^{[6
]}

Goto, Y. ^{[7
]}

Lu, S. ^{[8
]}

Ardizzoni, A. ^{[9
]}

Barlesi, F. ^{[10
]}

De Marchi, P. ^{[11
]}

Paz-Ares, L. ^{[12
]}

Spigel, D. R. ^{[13
]}

Thomas, M. ^{[14
]}

Garon, E. B. ^{[15
]}

Leung, M. ^{[16
]}

Baum, J. ^{[17
]}

Zewen, Z. ^{[18
]}

Mookerjee, B. ^{[16
]}

Yang, J. C-H. ^{[19
]}

机构：

[1] Yonsei Univ, Coll Med, Dept Internal Med, Seoul, South Korea

[2] Taichung Vet Gen Hosp, Dept Internal Med, Div Chest Med, Taichung, Taiwan

[3] ChonnamNatl Univ, Lung Canc Clin, Dept Internal Med, Hwasun Hosp, Jeollanam Do, South Korea

[4] Songklanagarind Hosp, Fac Med, Dept Internal Med, Songkhla, Thailand

[5] Chiang Mai Univ, Fac Med, Dept Surg, Chiang Mai, Thailand

[6] Chang Gung Mem Hosp, Dept Thorac Med, Taoyuan, Taiwan

[7] Natl Canc Ctr, Dept Thorac Oncol, Tokyo, Japan

[8] Shanghai Chest Hosp, Dept Med Oncol, Shanghai, Peoples R China

[9] St Orsola Malpighi Univ Polyclin, Dept Oncol & Hematol, Bologna, Italy

[10] Aix Marseille Univ, Dept Med Oncol, Marseille, France

[11] Hosp Canc Barretos, Dept Med Oncol, Sao Paulo, SP, Brazil

[12] Univ Hosp 12 Octubre, Dept Med Oncol, Madrid, Spain

[13] Sarah Cannon Res Inst, Dept Med Oncol, Nashville, TN USA

[14] Thoraxklin Univ Klinikum Heidelberg, Internist Onkol Thoraxtumoren, Dept Thorac Oncol Internal Med, German Ctr Lung Res DZL,TLRC H, Heidelberg, Germany

[15] UCLA TRIO US Network, David Geffen Sch Med, Dept Hematol Oncol, Los Angeles, CA USA

[16] Novartis Pharmaceut, Dept Oncol, E Hanover, NJ USA

[17] Novartis Inst BioMed Res, Dept Oncol, Cambridge, MA USA

[18] Novartis Pharmaceut, Dept Biostat, E Hanover, NJ USA

[19] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan

来源：

ANNALS OF ONCOLOGY | 2019年 / 30卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

531TiP

引用

页数：2

共 50 条

[21] PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
Paz-Ares, L.
Villegas, A.
Daniel, D.
Baz, D. V.
Murakami, S.
Hui, R.
Yokoi, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Jiang, H.
Huang, Y.
Dennis, P. A.
Ozguroglu, M.
ANNALS OF ONCOLOGY, 2017, 28
[22] PACIFIC: a double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
Schulz, C.
Laack, E.
Wolff, T.
Rueckert, A.
Reck, M.
Faehling, M.
Fischer, J. R.
de Wit, M.
ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 270 - 270
[23] A randomized placebo-controlled phase III study of docetaxel/carboplatin with celecoxib in patients (pts) with advanced non-small cell lung cancer (NSCLC): The NVALT-4 study
Groen, H.
Hochstenbag, M. M.
van Putten, J. W.
Vincent, A.
Dalesio, O.
Biesma, B.
Smit, H. J.
Termeer, A.
van den Borne, B. E.
Schramel, F. M.
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
[24] CANOPY-1: Phase 3 Study of Canakinumab/Placebo plus Pembrolizumab plus Platinum-Chemotherapy in Untreated Stage IIIB-IV NSCLC Pts
Felip, E.
Castro, G.
Greystoke, A.
Solomon, B.
Tan, D.
Passos, V.
Deudon, S.
Louveau, A.
Johnson, B.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S645 - S645
[25] CCTG BR.31: A global, double-blind placebo-controlled, randomized phase III study of adjuvant durvalumab in completely resected non-small cell lung cancer (NSCLC)
Goss, G.
Darling, G. E.
Westeel, V.
Nakagawa, K.
Massuti Sureda, B.
Perrone, F.
McLachlan, S-A.
Kang, J. H.
Wu, Y-L.
Dingemans, A-M. C.
Dziadziuszko, R.
Okada, M.
Greillier, L.
Audigier-Valette, C.
Sugawara, S.
Nadal, E.
Catino, A.
Stockler, M. R.
Ding, K.
O'Callaghan, C.
ANNALS OF ONCOLOGY, 2024, 35 : 1238 - 1238
[26] Randomized double-blind placebo-controlled phase II/III trial in adjuvant NSCLC patients with the candidate cancer vaccine IGN101
Loibner, H.
Eckert, H.
Stoiber, W.
Groiss, F.
Stoelben, E.
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
[27] Biomarker analyses from SATURN, a phase III placebo-controlled study of erlotinib as first-line maintenance therapy for advanced NSCLC
Brugger, W.
Kim, J. -H.
Hansen, O.
Sulllivan, R.
White, S.
Lee, J. -S.
Schlegel, M.
Noe, J.
Nagelmeier, I.
Cappuzzo, F.
EJC SUPPLEMENTS, 2009, 7 (02): : 559 - 559
[28] Molecular markers and clinical outcome with erlotinib: results from the phase III placebo-controlled SATURN study of maintenance therapy for advanced NSCLC
Brugger, Wolfram
Kim, Joo-Hang
Hansen, Olfred
Sullivan, Richard N.
White, Shane C.
Lee, Jung-Shin
Klingelschmitt, Gaelle
Spleiss, Olivia
Nagelmeier, Iris
Cappuzzo, Federico
JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S348 - S349
[29] Aspirin after standard adjuvant therapy for colorectal cancers (ASCOLT): An international, phase III, randomised, placebo-controlled trial
Chia, J. W. K.
Segelov, E.
Deng, Y.
Wang, W.
Ho, G. F.
Sharma, A.
Ding, K.
Chen, G.
Jeffery, G. M.
Nott, L. M.
Zielinski, R.
Ahn, J. B.
Chao, T. Y.
Yau, T.
Nabilah, S.
Gandhi, M.
Rothwell, P.
Simes, J.
Ali, R.
Toh, H. C.
ANNALS OF ONCOLOGY, 2023, 34 : S1269 - S1269
[30] CANOPY-1: Phase 3 Study of Canakinumab/Placebo plus Pembrolizumab plus PlatinumChemotherapy in Untreated Stage IIIB-IV NSCLC Patients
Johnson, B. E.
Castro, G. D.
Greystoke, A.
Solomon, B.
Tan, D. S. W.
Passos, V.
Deudon, S.
Louveau, A. L.
Felip, E.
JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1136 - S1136

← 1 2 3 4 5 →